AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Inspire Medical Systems under investigation for securities violations.
ByAinvest
Tuesday, Aug 12, 2025 9:29 am ET1min read
• Bloomberg financial analyst investigating Inspire Medical Systems • Allegations of false/misleading statements and undisclosed information • Company lowered Q2 revenue guidance, delayed rollout of Inspire V system • Shares fell 40.6% in intraday trading on August 5, 2025 • Investor losses encouraged to contact Brian Schall of the Schall Law Firm • Schall Law Firm filing claims on behalf of investors under securities laws • Allegations focus on Inspire Medical Systems' Q2 earnings report and guidance revision
Los Angeles, CA – August 12, 2025 – The Schall Law Firm has announced that it is investigating claims on behalf of investors of Inspire Medical Systems, Inc. (NYSE: INSP) for potential violations of the securities laws. The investigation centers on whether the company issued false or misleading statements and/or failed to disclose pertinent information to investors.On August 4, 2025, Inspire reported its Q2 earnings, lowering its full-year revenue guidance and disclosing delays in the rollout of its "Inspire V" system. The company revealed that treatment centers had postponed the adoption of the new system due to not being able to bill Medicare until July 1, 2025. This news led to a significant drop in shares, with Inspire's stock falling by almost 40.6% in intraday trading on August 5, 2025 [1].
The Schall Law Firm is encouraging shareholders who suffered losses to contact Brian Schall, Esq., at 310-301-3335 or via email at bschall@schallfirm.com to discuss their rights. The firm specializes in securities class action lawsuits and shareholder rights litigation and represents investors worldwide [2].
Separately, Levi & Korsinsky has also commenced an investigation into Inspire Medical Systems, Inc. for possible violations of federal securities laws. The firm notes that Inspire's stock price fell by $46.44 per share following the release of its Q2 earnings report and guidance revision [3].
These investigations come amidst growing scrutiny over Inspire's financial disclosures and the accuracy of its earnings guidance. Investors are advised to stay informed and consult with legal professionals for guidance on potential legal action.
References:
[1] https://www.marketscreener.com/news/insp-investors-have-opportunity-to-join-inspire-medical-systems-inc-fraud-investigation-with-the-s-ce7c51dadb89f52d
[2] https://www.prnewswire.com/news-releases/insp-investors-have-opportunity-to-join-inspire-medical-systems-inc-fraud-investigation-with-the-schall-law-firm-302527267.html
[3] https://www.tradingview.com/news/reuters.com,2025-08-11:newsml_NFCywmw9:0-lost-money-on-inspire-medical-systems-inc-insp-possible-fraud-contact-levi-korsinsky-today/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet